AC Immune S.A.

NASDAQ:ACIU

Biotechnology

Healthcare
$2.10 +1.71%

+$0.04 today

Market cap
$213.72M
Beta
1.56
P/E (TTM)
-2.9
EPS (TTM)
-$0.67
52W Low $1.65High $4.00

Volume 0.08M

Average 0.32M

ACIU Other Investing Activities

Investing cash flows not reported separately.

AC Immune S.A.NASDAQ: ACIU

Other Investing Activities · Q4 FY2025 · quarter ended Dec 2025

Other investing activities dips below year-ago levels

Q4 FY2025 other investing activities of CHF 211 (cash outflow) fell 100.0% year over year, behind the +146.2% change in trailing-twelve-month other investing activities.

Context

  • Other investing activities amounted to 4.5% of revenue in FY2025, down 378.9 pp from a year earlier.
  • Other investing activities increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -100.0% toward the trailing-twelve-month pace of +146.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
-CHF 211-100.0% QoQ
Last fiscal yearDec 2025
-CHF 162.36K-99.8% YoY
LTMDec 2025
CHF 48.33M+146.2% YoY
Other Investing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-99.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Investing Activities history

CHF · from the cash flow

Latest · FY2025
(162.36K) CHF
Year-over-year change
+99.8%

Other Investing Activities vs competitors

How ACIU compares with its peers on the latest reported figures

  • Peers report in different currencies, so other investing activities is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +146.2% is the 2nd highest of 4, against a peer median of -116.6%.
  • Other investing activities amounts to 1352.7% of revenue for ACIU, versus a peer median of 93.3%.
ACIU Competitors
Other Investing Activities for ACIU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AMRNAmarin Corporation plcLTM Mar 2026$200.5M USD-464.5%—93.3%
SLNSilence Therapeutics plcLTM Mar 2026$182.54M USD——19808.8%
ACIUAC Immune S.A.LTM Dec 2025CHF 48.33M CHF+146.2%—1352.7%
LYELLyell Immunopharma, Inc.LTM Mar 2026$41.17M USD——132809.7%
CLLSCellectis S.A.LTM Mar 2026$2.26M USD-116.6%—3.3%
MREOMereo BioPharma Group plcLTM Mar 2026$299.5K USD+200.2%—59.9%
DRTSAlpha Tau Medical Ltd.LTM Dec 2025$0 USD———
ANROAlto Neuroscience, Inc.LTM Mar 2026$0 USD———
ANNXAnnexon, Inc.LTM Mar 2026$0 USD———
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$0 USD———
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$0 USD———
Peer median (excluding ACIU) —-116.6%—93.3%

Competitors are the stored peer set for ACIU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(73M)(70.75M)(54.23M)(50.92M)(67.28M)
Depreciation & Amortization2.41M2.36M2.22M2.16M2.39M
Deferred Income Tax130K0000
Stock-Based Compensation4.13M3.33M4.37M5.47M0
Change in Working Capital6.84M(8.43M)(15.16M)107.51M(6.47M)
Accounts Receivables(99K)603K(14.8M)13.55M877.68K
Inventory00000
Accounts Payables0000(565.39K)
Other Working Capital6.94M(9.04M)(360K)93.96M(6.78M)
Other Non-Cash Items(6.2M)(72K)2.41M1.61M5.21M
Operating Cash Flow(65.69M)(73.57M)(60.41M)65.84M(66.15M)
Capital Expenditures(2.64M)(1.24M)(801K)(576K)(859.54K)
Acquisitions (Net)000014.33K
Purchases of Investments00000
Sales of Investments000061.69M
Other Investing Activities(51.03M)25M66.45M(104.71M)(162.36K)
Investing Cash Flow(53.66M)23.76M65.65M(105.29M)60.69M
Debt Repayment22.95M(569K)(548K)(683K)(1.03M)
Common Stock Issued17.8M7K43.8M111K5.73K
Common Stock Repurchased0(8K)000
Dividends Paid00000
Other Financing Activities(6K)(776K)0(548K)46.13K
Financing Cash Flow40.75M(1.35M)43.25M(1.12M)(974.14K)
Effect of Forex Changes(70K)521K(1.58M)(1.65M)1.51M
Net Change in Cash(78.68M)(50.63M)46.91M(42.22M)(4.92M)
Free Cash Flow(68.32M)(74.81M)(61.21M)65.27M(67.01M)

AC Immune S.A.

NASDAQ:ACIU

Intrinsic Alpha fair value

Locked

Current Price

$2.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.